- Home
- PMCB vs PPBT Comparison
PMCB vs PPBT Comparison
Compare PMCB & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- PPBT
- Stock Information
- Founded
- PMCB 1996
- PPBT 2010
- Country
- PMCB United States
- PPBT Israel
- Employees
- PMCB N/A
- PPBT N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- PPBT Health Care
- Exchange
- PMCB Nasdaq
- PPBT Nasdaq
- Market Cap
- PMCB 6.6M
- PPBT 5.5M
- IPO Year
- PMCB N/A
- PPBT N/A
- Fundamental
- Price
- PMCB $0.94
- PPBT $0.81
- Analyst Decision
- PMCB
- PPBT Strong Buy
- Analyst Count
- PMCB 0
- PPBT 1
- Target Price
- PMCB N/A
- PPBT $33.00
- AVG Volume (30 Days)
- PMCB 51.4K
- PPBT 21.3M
- Earning Date
- PMCB 12-12-2025
- PPBT 11-14-2025
- Dividend Yield
- PMCB N/A
- PPBT N/A
- EPS Growth
- PMCB N/A
- PPBT N/A
- EPS
- PMCB 0.01
- PPBT N/A
- Revenue
- PMCB N/A
- PPBT N/A
- Revenue This Year
- PMCB N/A
- PPBT N/A
- Revenue Next Year
- PMCB N/A
- PPBT N/A
- P/E Ratio
- PMCB $152.54
- PPBT N/A
- Revenue Growth
- PMCB N/A
- PPBT N/A
- 52 Week Low
- PMCB $0.80
- PPBT $0.53
- 52 Week High
- PMCB $2.42
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- PMCB 40.17
- PPBT 56.69
- Support Level
- PMCB $0.92
- PPBT $0.85
- Resistance Level
- PMCB $1.03
- PPBT $1.41
- Average True Range (ATR)
- PMCB 0.04
- PPBT 0.08
- MACD
- PMCB -0.01
- PPBT 0.07
- Stochastic Oscillator
- PMCB 8.34
- PPBT 36.82
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.